NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-DK-17-005 from the NIH Guide for Grants and Contracts
Notice NOT-AG-16-084 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-17-604 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support go/no-go decisions about further development or testing of the intervention. This FOA supports the development and testing of innovative psychosocial intervention approaches where the target and/or the intervention strategy is novel. Targets might include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms associated with risk for, causation of, or maintenance of a mental disorder. Eligible psychosocial interventions strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. This FOA supports the development and testing of novel psychosocial interventions, as defined above, as monotherapies or as augmentations to standard treatment. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of the interventions impact on a target (a process or mechanism associated with risk for, causation, or maintenance of a clinical condition), that is, its target engagement. Contingent on meeting go/no-go milestones in the R61 phase, up to 3 years of additional support (R33 phase) may be provided for studies to replicate target engagement and relate change in the intervention target/mechanism to clinical benefit. Ultimately, this R61/R33 FOA is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders, or for preventing mental disorders among those at risk.
Funding Opportunity RFA-MH-17-606 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support go/no-go decisions about further development or testing of the intervention. This FOA supports the development and testing of innovative psychosocial intervention approaches where the target and/or the intervention strategy are novel. Targets might include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms associated with risk for, causation of, or maintenance of a mental disorder. Eligible psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. This FOA supports the development and testing of novel psychosocial interventions, as defined above, as monotherapies or as augmentations to standard treatment. Support will be provided for up to 3 years for studies to replicate previous target engagement findings, and relate change in the intervention target/mechanism to clinical benefit. Ultimately, this FOA is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders, or for preventing mental disorders among those at risk.
Funding Opportunity RFA-MH-17-600 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the early stage testing of pharmacologic interventions with novel mechanisms of action, or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g. schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder, etc.). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect. The R61/R33 FOAs are intended to support biphasic high risk applications. Applicants looking for a single phased award that does not need the developmental (R61) phase should apply to companion RFA-MH-17-602.
Funding Opportunity PAR-17-083 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages grant applications for Biomedical Technology Resource Centers (BTRCs). BTRCs are national resource centers for conducting research and development on new technologies that are driven by the needs of basic, translational, and/or clinical researchers. BTRCs also make their technologies available to other investigators, train members of the research community in the use of the technologies, and disseminate the technologies broadly.
Funding Opportunity PA-17-084 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites research grant applications studying mechanisms of HIV-1 persistence and eradication strategies specifically focused on the central nervous system (CNS) in the context of viral suppression. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.
Funding Opportunity PAR-17-076 from the NIH Guide for Grants and Contracts. The High-End Instrumentation (HEI) Grant Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of expensive, specialized, commercially available instruments or integrated systems that cost at least $600,001. The maximum award is $2,000,000. Types of instruments supported include, but are not limited to: X-ray diffraction systems, nuclear magnetic resonance (NMR) and mass spectrometers, DNA and protein sequencers, biosensors, electron and confocal microscopes, cell-sorters, and biomedical imagers.
Funding Opportunity RFA-MD-17-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications that propose to develop a product, process or service for commercialization with the aim of reducing disparities in healthcare access and health outcomes and in preventing disease and improving health in one or more NIH-defined health disparity population group(s). Appropriate technologies should be effective, affordable, culturally acceptable, and deliverable to racial/ethnic minorities, low-income and rural populations.
Funding Opportunity RFA-MD-17-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications that propose to develop a product, process or service for commercialization with the aim of reducing disparities in healthcare access and health outcomes in one or more NIH-defined health disparity population group(s). Appropriate technologies should be effective, affordable, culturally acceptable, and deliverable to racial/ethnic minorities, low-income and rural populations.
Notice NOT-FD-17-001 from the NIH Guide for Grants and Contracts
Notice NOT-HL-16-479 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-075 from the NIH Guide for Grants and Contracts. The Shared Instrumentation for Animal Research (SIFAR) Grant Program encourages applications from groups of NIH-funded investigators to purchase or upgrade scientific instruments necessary to carry out animal experiments in all areas of biomedical research supported by the NIH. Applicants may request clusters of commercially available instruments configured as specialized integrated systems or as series of instruments to support a thematic workflow in a well-defined area of research using animals or related materials. Priority will be given to specialized clusters of instruments and to uniquely configured systems to support innovative and potentially transformative investigations. Requests for a single instrument will be considered only if the instrument is to be placed in a barrier facility. This Funding Opportunity Announcement (FOA) supports requests for state-of-the art commercially available technologies needed for NIH-funded research using any vertebrate and invertebrate animal species. It is expected that the use of the awarded instruments will enhance the scientific rigor of animal research and improve the reproducibility of experimental outcomes. One item of the requested instrumentation must cost at least $50,000. No instrument in a cluster can cost less than $20,000. There is no maximum price requirement; however, the maximum award is $750,000.
Funding Opportunity PA-17-077 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites R18 grant applications for research that demonstrates how health information technology (IT) can improve patient-centered health outcomes and quality of care in primary care and other ambulatory settings through the scale and spread of successful, health IT-enabled practice models that use patient-reported outcome (PRO) measures to achieve these objectives.
Funding Opportunity PAR-17-074 from the NIH Guide for Grants and Contracts. The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of expensive, specialized, commercially available instruments or integrated systems that cost at least $50,000. There is no maximum price requirement; however, the maximum award is $600,000. Types of instruments supported include, but are not limited to: X-ray diffractometers, mass and nuclear magnetic resonance (NMR) spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, and biomedical imagers.
Funding Opportunity RFA-RM-17-001 from the NIH Guide for Grants and Contracts. The purpose of this small research grant Funding Opportunity Announcement (FOA) is to foster collaboration between computational scientists, metabolomics experts, and biomedical researchers in developing, piloting, and/or validating novel bioinformatic approaches that address current analytical hurdles in metabolomics data. A goal of providing powerful approaches that will be useful to biomedical researchers, as well as bioinformaticians, is particularly encouraged. Projects are not intended to supplement ongoing metabolomics analyses, but to provide a tool for broader use by the biomedical research community. Projects are expected to use existing, publicly available metabolomics data and complement the efforts and resources of the Common Fund Metabolomics Program.
Funding Opportunity RFA-AT-17-001 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit UG3/UH3 phased cooperative agreement research applications to conduct efficient, large-scale pragmatic clinical trial Demonstration Projects within the NIH-DoD-VA Pain Management Collaboratory on non-pharmacological approaches to pain management and other co-morbid conditions in U.S. military personnel, veterans and their families. This program will be referred to as the NIH-DoD-VA Pain Management Collaboratory program. Awards made under this FOA will initially support a two-year milestone-driven planning phase (UG3), with possible transition to a pragmatic trial Demonstration Project implementation phase (UH3). UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The overall goal of this initiative, jointly supported by the NIH, DoD, and VA, is to develop the capacity to implement cost-effective large-scale clinical research in military and veteran health care delivery organizations focusing on non-pharmacological approaches to pain management and other comorbid conditions. The NIH, DoD, and VA expect to: establish a Coordinating Center that will provide national leadership and technical expertise for all aspects of health care system (HCS_- focused research including assistance to UG3/UH3 grant applicants. Primary outcomes of treatment interventions include assessing pain and pain reduction, ability to function in daily life, quality of life, and medication usage/reduction/discontinuation. Secondary outcomes focusing on assessing comorbid conditions or those co-occurring with high frequency in this population are also of interest under the FOA.
Funding Opportunity RFA-AT-17-002 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit applications for a Coordinating Center (CC) to provide national leadership for the NIH-DoD-VA Health Care Systems (HCS) Research Collaboratory program on non-pharmacological approaches to pain management and comorbidities in U.S. military personnel, veterans and their families. For brevity, this initiative will be referred to as the NIH-DoD-VA Pain Management Collaboratory. Coordinating Center applicants will need to: 1) develop, adapt, and adopt technical and policy guidelines and best practices for the effective conduct of research in partnership with health care systems focused on military personnel, veterans, and their families; 2) work collaboratively with and provide technical, design, and other support to Demonstration Project teams, to develop and implement a pragmatic trial protocol; and 3) disseminate widely Collaboratory-endorsed policies and best practices and lessons learned in the Demonstration Projects for implementing research within health care settings. The Coordinating Center will also serve as the central resource for the activities of the NIH-DoD-VA Pain Management Collaboratory program, including providing administrative support for a Steering Committee and its subcommittees.
Funding Opportunity PAR-17-079 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages health services research designed to increase the public health impact of Food and Drug Administration (FDA)-approved pharmacotherapies for the treatment of alcohol use disorder. Significant progress is needed in developing generalizable, scalable, cost-effective strategies to move these evidence-based interventions into the mainstream of alcohol use disorder treatment, in both general medical and specialty care settings. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) seeks applications to conduct hypothesis-driven research to identify effective methods for increasing the utilization of currently-available medications, by addressing their acceptability (to prescribers and patients), perceived effectiveness, affordability, and feasibility of use within existing care delivery systems.
Notice NOT-NS-17-010 from the NIH Guide for Grants and Contracts